News
News
Press Release
Sysmex Expands Portfolio and Accelerates Global Expansion through Acquisition of JEOL's Clinical Chemistry Testing Business
Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announces that it has resolved to acquire the medical equipment business (“Target Business”) of JEOL Ltd. (HQ: Akishima, Tokyo; President & CEO: Izumi Oi; “JEOL”) and has entered into a share transfer agreement with JEOL on September 2, 2025. Under this agreement, JEOL is to establish a new company (HQ: Musashimurayama, Tokyo; “Target Company”), which will assume the Target Business through an absorption-type company split; thereafter, Sysmex will acquire all of the Target Company's shares (making it a wholly owned subsidiary). The share transfer is expected to be completed in April 2026, subject to the completion of various procedures and approval from the relevant authorities.
The Clinical Chemistry Analyzer1 BioMajesty™2 (“BioMajesty”), owned by the Target Business, is equipped with proprietary technology that enables the use of minimal sample volumes and reduced reagent consumption, and has achieved a high market share in Japan. Meanwhile, in overseas markets, the Target Business operates through OEMs and distributors. Sysmex entered into a basic sales agreement with JEOL in 2010 and has been selling mid-sized models in the Asia Pacific region. As both companies have explored deeper partnership and business expansion opportunities in emerging markets, they have reached a shared understanding that leveraging Sysmex’s strengths in its global sales and service network will most effectively enhance business value.
Acquiring the highly competitive and high-quality BioMajesty will accelerate the realization of Sysmex’s Long-Term Corporate Strategy (VA33), with fiscal 2033 as the final year, and create diverse business synergies. In addition to further developing the partnerships with reagent manufacturers that have been built to date, Sysmex will expand new collaborative opportunities worldwide and strengthen its product portfolio. Furthermore, in addition to expanding its business in the clinical chemistry and immunochemistry fields, where its reagent business is expected to grow substantially, Sysmex will leverage its comprehensive product portfolio and strengths in sales and customer care to meet robust testing needs in the global market, offering a full range of basic screening tests.
Sysmex will continue to strengthen its business as a comprehensive supplier in the diagnostics field and further enhance its capabilities to deliver cost-effective testing solutions to customers worldwide.
| 1 | Clinical Chemistry Analyzer: | |
| An analyzer that utilizes bodily fluids, such as blood and urine, as specimens to measure various components, including glucose, cholesterol, proteins, and enzymes. In addition to general clinical chemistry parameters, such devices are now capable of measuring a broad range of tests, including immunoassays, tumor markers, and selected hemostasis-related parameters. | ||
| 2 | BioMajesty™ Series: | |
| This series of clinical chemistry analyzers employ a unique sample dilution method, enabling the use of minimal sample and reagent volumes. The extensive lineup ranges from the high-end JCA-BM8000 series, designed for high-speed, large-volume processing, to the low-end JCA-BM6010G, a space-saving model that combines multifunctionality and ease of use, meeting the diverse needs of testing laboratories. |
About Sysmex Corporation
|
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit www.sysmex.co.jp/en/. |
About JEOL Ltd.
|
- The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.